Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

  • days left to enroll
  • participants needed
  • sponsor
    University of Nebraska
Updated on 26 January 2022
ejection fraction
monoclonal antibodies
granulocyte colony stimulating factor
measurable disease
cell transplantation
bone marrow procedure
induction therapy
colony stimulating factor
chemotherapy regimen
monoclonal protein


This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and post-transplant. The primary end point will be tetanus vaccine immune responses post-transplant.



  1. To compare the cellular and humoral vaccine response post-transplant between the two arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays
  2. To determine the feasibility and safety of this approach


  1. To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19, NK, T-cells), in addition to T-cell phenotype markers between the two arms.
  2. To compare post-transplant recovery of T-regs and MDSCs between the two arms.
  3. To compare progression free survival (PFS) at 2 years post-transplant

Condition Plasma Cell Myeloma
Treatment melphalan, therapeutic autologous lymphocytes, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine, XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
Clinical Study IdentifierNCT02700841
SponsorUniversity of Nebraska
Last Modified on26 January 2022


Yes No Not Sure

Inclusion Criteria

Age 19 years to 70 years old at time of study entry (consent)
Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group (IMWG) criteria
Must have measurable disease defined as: for secretory MM, serum monoclonal protein 1.0 g/dL, urine monoclonal protein 200 mg/24 hrs, and involved free light chain 10 mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage 30%
Must have standard risk myeloma (see exclusion criterion 4)
Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary clinically for cytoreduction)
Able to understand and sign a consent form
Creatinine clearance equal or > 60 ml/min (calculated)
Ejection fraction equal or > 50% before admission for transplant as per institutional standards. Patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to be cleared by cardiology as per institutional BMT standards
Serum bilirubin, ALT, AST less than 3 X upper limit of normal
FVC, FEV1 or DLCO >50% predicted before admission for transplant as per institutional standards. Patients on home oxygen are not allowed on the protocol
No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of the start of the induction therapy)
KPS 70%or ECOG 0-2
Must be eligible to receive Melphalan dose of 200mg/m2
A female of child-bearing potential, must have two negative urine pregnancy test results within 10 to 14 days prior to starting the first dose of vaccine pre-transplant as a way of ensuring safe transplant planning

Exclusion Criteria

Participation in another clinical study with an investigational product during the last 28 days
Prior stem cell transplant (either autologous or allogeneic)
Creatinine clearance < 60 ml/min (calculated)
High risk MM defined as those with the following disease, fluorescence in situ hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14), t(14;16), t(14;20), >1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell leukemia (primary or secondary), or subjects who failed to achieve PR to induction therapy (i.e. VRd) and required salvage induction prior to AHSCT
Documented central nervous system or extramedullary disease
Significant organ dysfunction deemed to carry inappropriate risk for AHSCT
Intention or plans for cyclophosphamide mobilization
Known allergic reactions after previous tetanus diphtheria vaccination or had a condition of Guillain Barre Syndrome (GBS)
Known active hepatitis B, C or HIV infections on initial assessment
Enrollment on any other transplant related protocols
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note